Retinal vein occlusion (RVO) ranks as the second most prevalent retinal vascular disease, representing a significant cause of vision loss globally. The development of macular edema (ME) secondary to RVO is a major complication that severely impairs central visual acuity and quality of life. As a chronic condition often linked to systemic factors, its clinical management demands a multifaceted and proactive strategy. This article provides a systematic review of the contemporary clinical management of RVO-ME. It elucidates how current principles have shifted from traditional, reactive interventions toward a comprehensive model. This modern paradigm emphasizes precise baseline assessment, individualized treatment regimens leveraging anti-VEGF therapy and steroids, integrated systemic management of risk factors, and structured long-term follow-up. This systematic discussion aims to consolidate current evidence and offer practical guidance for optimizing patient care and visual outcomes.

Yi Xiang, Yanni Zhu. Beyond Traditional Treatment: A Holistic Approach to Managing Retinal Vein Occlusion with Macular Edema. International Journal of Frontiers in Medicine (2025), Vol. 7, Issue 4: 128-136. https://doi.org/10.25236/IJFM.2025.070416.

[1] Scott I U, Campochiaro P A, Newman N J, et al. Retinal vascular occlusions[J]. Lancet (London, England), 2020, 396(10266): 1927-1940.

[2] Ozer M D, Batur M, Mesen S, et al. Evaluation of the Initial Optical Coherence Tomography Parameters in Anticipating the Final Visual Outcome of Central Retinal Vein Occlusion[J]. Journal of Current Ophthalmology, 2020, 32(1): 46-52.

[3] Song P, Xu Y, Zha M, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors[J]. Journal of Global Health, 2019, 9(1): 010427.

[4] Zhou J Q, Xu L, Wang S, et al. The 10-year incidence and risk factors of retinal vein occlusion: the Beijing eye study[J]. Ophthalmology, 2013, 120(4): 803-808.

[5] Nicholson L, Talks S J, Amoaku W, et al. Retinal vein occlusion (RVO) guideline: executive summary[J]. Eye (London, England), 2022, 36(5): 909-912.

[6] Ponto K A, Scharrer I, Binder H, et al. Hypertension and multiple cardiovascular risk factors increase the risk for retinal vein occlusions: results from the Gutenberg Retinal Vein Occlusion Study[J]. Journal of Hypertension, 2019, 37(7): 1372-1383.

[7] Vieira M J, Campos A, do Carmo A, et al. Thrombophilic risk factors for retinal vein occlusion[J]. Scientific Reports, 2019, 9(1): 18972.

[8] Kang Q, Yang C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications[J]. Redox Biology, 2020, 37: 101799.

[9] Pan M, Zhou P, Guo J, et al. Elevated Neutrophil Counts, Triglycerides, Monocyte/High-Density Lipoprotein Ratios, and Lower High-Density Lipoprotein in Patients with Retinal Vein Occlusion[J]. Ophthalmic Research, 2023, 66(1): 265-271.

[10] Hirano Y, Suzuki N, Tomiyasu T, et al. Multimodal Imaging of Microvascular Abnormalities in Retinal Vein Occlusion[J]. Journal of Clinical Medicine, 2021, 10(3): 405.

[11] Schmidt-Erfurth U, Garcia-Arumi J, Gerendas B S, et al. Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA)[J]. Ophthalmologica. Journal International D’ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde, 2019, 242(3): 123-162.

[12] Otawa T, Noma H, Yasuda K, et al. Intravitreal ranibizumab improves macular sensitivity in patients with central retinal vein occlusion and macula edema[J]. BMC ophthalmology, 2022, 22(1): 247.

[13] Chen C L, Wang R K. Optical coherence tomography based angiography [Invited][J]. Biomedical Optics Express, 2017, 8(2): 1056-1082.

[14] Koulisis N, Kim A Y, Chu Z, et al. Quantitative microvascular analysis of retinal venous occlusions by spectral domain optical coherence tomography angiography[J]. PloS One, 2017, 12(4): e0176404.

[15] Kashani A H, Chen C L, Gahm J K, et al. Optical coherence tomography angiography: A comprehensive review of current methods and clinical applications[J]. Progress in Retinal and Eye Research, 2017, 60: 66-100.

[16] Zhao X, Lin Z, Yu S, et al. An artificial intelligence system for the whole process from diagnosis to treatment suggestion of ischemic retinal diseases[J]. Cell Reports. Medicine, 2023, 4(10): 101197.

[17] An W, Han J. Research progress of UWFFA and OCTA in retinal vein occlusion: A review[J]. European Journal of Ophthalmology, 2021, 31(6): 2850-2855.

[18] Huang S, Jin K, Gao Z, et al. Automated interpretation of retinal vein occlusion based on fundus fluorescein angiography images using deep learning: A retrospective, multi-center study[J]. Heliyon, 2024, 10(13): e33108.

[19] Castro C, Marques J H, Silva N, et al. Comparison of Color Fundus Photography and Multicolor Fundus Imaging for Detection of Lesions in Diabetic Retinopathy and Retinal Vein Occlusion[J]. Clinical Ophthalmology (Auckland, N.Z.), 2023, 17: 2515-2524.

[20] Flaxel C J, Adelman R A, Bailey S T, et al. Retinal Vein Occlusions Preferred Practice Pattern®[J]. Ophthalmology, 2020, 127(2): P288-P320.

[21] F S, Y S, J Z, et al. Mesenchymal stem cells-derived small extracellular vesicles alleviate diabetic retinopathy by delivering NEDD4[J]. Stem cell research & therapy, 2022, 13(1).

[22] Kazantzis D, Machairoudia G, Kroupis C, et al. Complete Blood Count-Derived Inflammation Indices and Retinal Vein Occlusion: A Case-Control Study[J]. Ophthalmology and Therapy, 2022, 11(3): 1241-1249.

[23] Brand C S. Management of retinal vascular diseases: a patient-centric approach[J]. Eye (London, England), 2012, 26 Suppl 2(Suppl 2): S1-16.

[24] Gerding H, Monés J, Tadayoni R, et al. Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel[J]. The British Journal of Ophthalmology, 2015, 99(3): 297-304.

[25] Kovach J L, Schwartz S G, Flynn H W, et al. Anti-VEGF Treatment Strategies for Wet AMD[J]. Journal of Ophthalmology, 2012, 2012: 786870.

[26] Zong Y, Kamoi K, Kurozumi-Karube H, et al. Safety of intraocular anti-VEGF antibody treatment under in vitro HTLV-1 infection[J]. Frontiers in Immunology, 2022, 13: 1089286.

[27] Ferro Desideri L, Traverso C E, Nicolò M, et al. Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration[J]. Pharmaceutics, 2023, 15(5): 1413.

[28] Nichani P A H, Popovic M M, Mihalache A, et al. Efficacy and Safety of Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Meta-Analysis[J]. Ophthalmologica. Journal International D’ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde, 2024, 247(5-6): 355-372.

[29] Liu W, Li Y, Cao R, et al. A systematic review and meta-analysis to compare the efficacy of conbercept with ranibizumab in patients with macular edema secondary to retinal vein occlusion[J]. Medicine, 2020, 99(21): e20222.

[30] Cui J, Sun D, Lu H, et al. Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study[J]. Eye (London, England), 2018, 32(2): 391-399.

[31] Ding X, Wang Y, Zou B, et al. Effect of Conbercept Treatment on Macular Edema and Microvascular Structure in Eyes with Retinal Vein Occlusions[J]. International Journal of General Medicine, 2022, 15: 7311-7318.

[32] Xing Q, Dai Y N, Huang X B, et al. Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysis[J]. International Journal of Ophthalmology, 2023, 16(7): 1145-1154.

[33] Carnevali A, Bacherini D, Metrangolo C, et al. Long term efficacy and safety profile of dexamethasone intravitreal implant in retinal vein occlusions: a systematic review[J]. Frontiers in Medicine, 2024, 11: 1454591.

[34] Hykin P, Prevost A T, Vasconcelos J C, et al. Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial[J]. JAMA ophthalmology, 2019, 137(11): 1256-1264.

[35] Scott I U, VanVeldhuisen P C, Ip M S, et al. Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial[J]. JAMA ophthalmology, 2018, 136(4): 337-345.

[36] Volkmann I, Knoll K, Wiezorrek M, et al. Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients’ persistence[J]. BMC ophthalmology, 2020, 20(1): 122.

[37] Gallardo M, Munk M R, Kurmann T, et al. Machine Learning Can Predict Anti-VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema[J]. Ophthalmology. Retina, 2021, 5(7): 604-624.

[38] Yap T E, Husein S, Miralles de Imperial-Ollero J A, et al. The efficacy of dexamethasone implants following anti-VEGF failure for macular oedema in retinal vein occlusion[J]. European Journal of Ophthalmology, 2021, 31(6): 3214-3222.

[39] Campochiaro P A, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study[J]. Ophthalmology, 2014, 121(1): 209-219.

[40] Narayanan R, Panchal B, Das T, et al. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1[J]. The British Journal of Ophthalmology, 2015, 99(7): 954-959.

[41] Haller J A, Bandello F, Belfort R, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results[J]. Ophthalmology, 2011, 118(12): 2453-2460.

[42] Ashraf M, Souka A A. R, Singh R P. Central retinal vein occlusion: modifying current treatment protocols[J]. Eye (London, England), 2016, 30(4): 505-514.

[43] Brown D M, Wykoff C C, Wong T P, et al. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial[J]. Retina (Philadelphia, Pa.), 2014, 34(9): 1728-1735.

[44] Feltgen N, Ogura Y, Boscia F, et al. Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies[J]. Ophthalmology. Retina, 2019, 3(7): 553-560.

[45] Hogg H D J, Talks S J, Pearce M, et al. Real-World Visual and Neovascularisation Outcomes from anti-VEGF in Central Retinal Vein Occlusion[J]. Ophthalmic Epidemiology, 2021, 28(1): 70-76.

[46] Ying J N, Li H, Zhang Y Y, et al. Application and progress of artificial intelligence technology in the segmentation of hyperreflective foci in OCT images for ophthalmic disease research[J]. International Journal of Ophthalmology, 2024, 17(6): 1138-1143.

[47] Nagasato D, Tabuchi H, Ohsugi H, et al. Deep-learning classifier with ultrawide-field fundus ophthalmoscopy for detecting branch retinal vein occlusion[J]. International Journal of Ophthalmology, 2019, 12(1): 94-99.

[48] Goel S, Sethi A, Pfau M, et al. Automated Region of Interest Selection Improves Deep Learning-Based Segmentation of Hyper-Reflective Foci in Optical Coherence Tomography Images[J]. Journal of Clinical Medicine, 2022, 11(24): 7404.

[49] Turczyńska M J, Krajewski P, Brydak-Godowska J E. Wide-Field Fluorescein Angiography in the Diagnosis and Management of Retinal Vein Occlusion: A Retrospective Single-Center Study[J]. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 2021, 27: e927782.

[50] Gawęcki M, Kiciński K. Advantages of the Utilization of Wide-Field OCT and Wide-Field OCT Angiography in Clinical Practice[J]. Diagnostics (Basel, Switzerland), 2024, 14(3): 321.

[51] Xu F, Yu X, Gao Y, et al. Predicting OCT images of short-term response to anti-VEGF treatment for retinal vein occlusion using generative adversarial network[J]. Frontiers in Bioengineering and Biotechnology, 2022, 10: 914964.